VANIQA 13.9 % — DIN 02243837
EFLORNITHINE HYDROCHLORIDE : 13.9 % · CIPHER PHARMACEUTICALS INC · CREAM · wholesale supply in Canada
Health Canada status: MARKETED
What is VANIQA?
VANIQA 13.9 % contains EFLORNITHINE HYDROCHLORIDE : 13.9 %. It is listed in the Health Canada Drug Product Database under DIN 02243837, held by CIPHER PHARMACEUTICALS INC, supplied as CREAM for TOPICAL administration. Health Canada currently lists it as marketed, status dated 04-Dec-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VANIQA used for?
VANIQA ® is indicated for slowing of the growth of unwanted facial hair in women. It is recommended as an adjunct to any hair removal technique. VANIQA ® Cream has only been studied on the face and neck of affected women. Usage should be limited to those areas.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 13.9 % |
|---|---|
| Dosage form | CREAM |
| Route | TOPICAL |
| Pack configuration (monograph) | 15, 30 and 60 g plastic tubes. |
| Storage | Store between 15 to 25°C. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Eflornithine |
|---|---|
| ATC code | D11AX16 |
| AHFS class | 56:12.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02243837 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243837 |
| Brand name | VANIQA |
| Generic / active ingredient | EFLORNITHINE HYDROCHLORIDE : 13.9 % |
| Market authorization holder | CIPHER PHARMACEUTICALS INC |
| Health Canada schedule | Prescription |
| ATC code | D11AX16 |
| ATC anatomical main group | D — Dermatologicals |
| ATC therapeutic subgroup | D11AX |
| Current status | MARKETED |
| Status date | 04-Dec-2015 |
| Original market date | 2003-04-01 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Apply a thin layer to affected areas of face and neck twice daily, at least 8 hours apart. Do not wash area for at least 4 hours after application.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to eflornithine or to any of the excipients of VANIQA.
Warnings and precautions
For topical use only. Avoid contact with eyes or mucous membranes. Transient stinging or burning may occur on abraded or broken skin.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC D11AX
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Pyrithione Zinc | 2 IN 1 ANTI-DANDRUFF SHAMPOO AND CONDITIONER · 2 IN 1 CONDITIONING DANDRUFF SHAMPOO · 2 IN 1 CONDITIONING DANDRUFF TREATMENT SHAMPOO · 2 IN 1 DANDRUFF RELIEF SHAMPOO & CONDITIONER · +343 more | 363 | 67 | Yes |
| Finasteride | AURO-FINASTERIDE 1MG · FINASTERIDE · JAMP FINASTERIDE TABLETS · MINT-FINASTERIDE · +5 more | 10 | 8 | Yes |
| Minoxidil, Topical | APO-GAIN LIQ 20MG/ML · GEN-MINOXIDIL LIQ 2% · HAIR REGROWTH FORMULA · HAIR REGROWTH TREATMENT · +11 more | 16 | 7 | Yes |
| Ivermectin | PMS-IVERMECTIN · ROSIVER | 2 | 2 | Yes |
| Hydroquinone | ACTIVE 4 · AFRICAN GOLD SKIN DISCOLORATION FADE CRM 2% · AMBI EXTRA SKIN DISCOLORATION FADE CREAM · BANISHING CREAM · +63 more | 67 | 1 | Yes |
| Brimonidine | ONRELTEA | 1 | 1 | Yes |
| Eflornithine | VANIQA | 1 | 1 | Yes |
| Deoxycholic Acid | BELKYRA | 1 | 1 | Yes |
| Other Dermatologicals | DERMAGRAN II OINTMENT-ONT TOP 0.25% · SHUR-CLENS SOLN 20% · WITCH HAZEL | 3 | 0 | Not in Canada |
| Monobenzone | BENOQUIN CRM 20% | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC D11A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| D11AH | Abrocitinib · Alitretinoin · Crisaborole · Delgocitinib · Dupilumab · +5 more | 25 | 19 |
| D11AF | Wart And Anti-Corn Preparations | 33 | 1 |
| D11AA | Antihidrotics | 397 | 0 |
| D11AC | Cetrimide · Medicated Shampoos · Others · Povidone-Iodine · Selenium Compounds · +1 more | 27 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is VANIQA called?
The same molecule, Eflornithine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ifinwil | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.